MS Research Studies

• Are between the ages of 55-80
• Are diagnosed with relapsing forms of MS
• Anticipate starting Briumvi® within 6 months, or have received your first dose of Briumvi® within 6 months

The purpose of this trial is to determine whether remibrutinib could be a safe and effective alternative therapy for use after anti-CD20 treatment (ocrelizumab) in the aging RMS population (40 up to 70 years old).

The BALANCE-MSS-1 Trial is evaluating a potential treatment option for muscle stiffness, also called spasticity, in adults with multiple sclerosis. Trial participation will last up to 20 weeks.

 Is multiple sclerosis (MS) making everyday tasks harder for you?

     We are inviting adults with MS to join the REMASTER Study, which is looking into an investigational study drug in a new class of disease-modifying therapies (DMTs).

You may be able to join the REMASTER Study if you:

• Are 18 to 65 years of age
•  Have a documented diagnosis of MS
• Have had no relapses within 2 years before starting the study
• Have some disability but are able to walk without assistance or with a walking aid such as a cane or crutch Study-related treatment, tests, and doctor visits are provided at no cost to you. Reimbursement for study-related expenses, such as meals, parking, or transportation may be available.